Publications

Journal Article
Review
Ppublish 79 citations
Electronic publication date
March 31, 2015

View on Pubmed.gov 25013808 | View on doi.org 10.1155/2014/87...

PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments.

Search for publications in this journal Biomed Res Int

Abstract

Noninvasive determination of integrin expression has become an interesting approach in nuclear medicine. Since the discovery of the first 18F-labeled cyclic RGD peptide as radiotracer for imaging integrin αvβ3 expression in vivo, there have been carried out enormous efforts to develop RGD peptides for PET imaging. Moreover, in recent years, additional integrins, including α5β1 and αvβ6 came into the focus of pharmaceutical radiochemistry. This review will discuss the tracers already evaluated in clinical trials and summarize the preliminary outcome. It will also give an overview on recent developments to further optimize the first-generation compounds such as [18F]Galacto-RGD. This includes recently developed 18F-labeling strategies and also new approaches in 68Ga-complex chemistry. Furthermore, the approaches to develop radiopharmaceuticals targeting integrin α5β1 and αvβ6 will be summarized and discussed.

References

Clin Cancer Res. 2012 Feb 1;18(3):839-49

J Cell Sci. 1995 Jun;108 ( Pt 6):2241-51

J Cell Biol. 1994 Feb;124(3):373-80

Cancer Res. 2009 Jul 15;69(14):5843-50

Cited by 79 citations (total)

Journal Article Research Support, Non-U.S. Gov't

H-CRRETAWAC-OH, a lead structure for the development of radiotracer targeting integrin α5β1?

Electronic publication date July 3, 2015

Search for publications in this journal Biomed Res Int

Roland Haubner [...] Olaf Prante et al.

Imaging of angiogenic processes is of great interest in preclinical research as well as in clinical settings. The most commonly...

Journal Article

Tc-3P-RGD2 molecular imaging targeting integrin in head and neck squamous cancer xenograft.

Electronic publication date August 1, 2015

Search for publications in this journal J Radioanal Nucl Chem

Bing Yan [...] Feng Wang et al.

Tc-3P-RGD2 and SPECT/CT were valuable tools for selecting patient likely benefit from integrin blocking therapy. To evaluate the feasibility...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances